Literature DB >> 8542601

Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction.

J R Müller1, G M Jones, M Potter, S Janz.   

Abstract

Interchromosomal recombinations between c-myc and immunoglobulin sequences can be found in preneoplastic lesions (oil granulomata) during pristane-induced plasmacytoma development in susceptible BALB/cAn mice. In this study we used a more sensitive approach, hybridization-enriched templates with nested PCR, to detect microclones with Ig alpha/c-myc recombinations in oil granulomata of susceptible and resistant mice. Recombinations were detected in as many as 73% (32/44) of plasmacytoma-susceptible BALB/cAn mice 30 days after an injection of pristane. Mice that are resistant to plasmacytoma induction can also harbor recombination-positive cells, but these are less frequent [2/20 DBA/2N, 8/20 (BALB/cAn x DBA/2N)F1, hereafter called CD2F1]. The clones in DBA/2N mice were small (< 400 cells), whereas in BALB/cAn, the oil granuloma harbored up to several thousand of these cells. We conclude that the molecular machinery for generating characteristic interchromosomal recombinations can be found in all strains of mice. Both the frequency of generating Ig alpha/c-myc recombinations and the expansion of recombination-positive cells are greater in susceptible mice than in resistant strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8542601

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Genetic reporter system for oncogenic Igh-Myc translocations in mice.

Authors:  M Takizawa; J S Kim; L Tessarollo; N McNeil; T J Waldschmidt; R Casellas; T Ried; S Janz
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

Review 2.  Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes.

Authors:  Rafael Casellas; Arito Yamane; Alexander L Kovalchuk; Michael Potter
Journal:  Immunology       Date:  2009-03       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.